Keith Loria

Researchers in China combined findings from MRI scans with clinical features to create a new predictive model for nonmuscle-invasive bladder cancer recurrence.

The PIVOT-006 trial is part of a larger national effort to evaluate cretostimogene’s safety and effectiveness in bladder cancer.

The differing regulation of key fibrotic pathways suggest that idiopathic pulmonary fibrosis involves dysregulation rather than just a speeded-up aging process.

Site neutrality payment, innovations in care delivery and value-based pricing of drugs could at least help to moderate the huge growth in expenditures.

The FDA approved the system in September 2025.

The deuterated form of deupirfenidone produced favorable results in an open-label extension study.

Therapies targeting extracellular matrix remodeling might hold the most promise.

Targeting S100A4 with a monoclonal antibody could comprehensively dampen disease-causing pathways, say drug developers.

CEO Scott Staszak spoke to Managed Healthcare Executive about the creation of a patient registry and other accomplishments.

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary sarcoidosis and SSc-ILD (scleroderma-related ILD), according to new trial data.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

More cases of interstitial lung disease (ILD) in India can be traced back to occupational exposure and other environmental causes compared with ILD in the U.S. A different set of exposures may affect the symptoms and course of the disease.

The Arthritis Foundation is funding a study to help predict the onset and progression of interstitial lung disease in rheumatoid arthritis patients

Kaminski and his colleagues were pioneers in applying high-throughput, genome-scale transcript profiling to advanced lung disease.

CDC researchers report a rate of 7.1 per 100,000, an increase from 5.3 per 100,000 in a previous study. But improved diagnosis of idiopathic pulmonary fibrosis might be a factor.

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic pulmonary fibrosis.

Researchers found that use of immunosuppressive medication was a strong protective factor, associated with a 60% reduction in mortality.

Research 'marries' traditional pathology with genomics.

The fundraiser is inspired, in part, by Michael Kuchwara, a famed Associated Press theater critic who died from pulmonary fibrosis in 2010